0|chunk|Methanolic Extract of Rhizoma Coptidis Inhibits the Early Viral Entry Steps of Hepatitis C Virus Infection

1|chunk|Hepatitis C Virus (HCV) remains an important public health threat with approximately 170 million carriers worldwide who are at risk of developing hepatitis C-associated end-stage liver diseases. Despite improvement of HCV treatment using the novel direct-acting antivirals (DAAs) targeting viral replication, there is a lack of prophylactic measures for protection against HCV infection. Identifying novel antivirals such as those that target viral entry could help broaden the therapeutic arsenal against HCV. Herein, we investigated the anti-HCV activity of the methanolic extract from Rhizoma coptidis (RC), a widely used traditional Chinese medicine documented by the WHO and experimentally reported to possess several pharmacological functions including antiviral effects. Using the cell culture-derived HCV system, we demonstrated that RC dose-dependently inhibited HCV infection of Huh-7.5 cells at non-cytotoxic concentrations. In particular, RC blocked HCV attachment and entry/fusion into the host cells without exerting any significant effect on the cell-free viral particles or modulating key host cell entry factors to HCV. Moreover, RC robustly suppressed HCV pseudoparticles infection of Huh-7.5 cells and impeded infection by several HCV genotypes. Collectively, our results identified RC as a potent antagonist to HCV entry with potential pan-genotypic properties, which deserves further evaluation for use as an anti-HCV agent.
1	97	105 carriers	Chemical	CHEBI_78059
1	262	272 antivirals	Chemical	CHEBI_22587
1	406	416 antivirals	Chemical	CHEBI_22587
1	645	653 medicine	Chemical	CHEBI_23888
1	759	768 antiviral	Chemical	CHEBI_22587
1	1317	1327 antagonist	Chemical	CHEBI_48706
1	CHEBI-CHEBI	CHEBI_78059	CHEBI_22587
1	CHEBI-CHEBI	CHEBI_78059	CHEBI_23888
1	CHEBI-CHEBI	CHEBI_78059	CHEBI_48706
1	CHEBI-CHEBI	CHEBI_22587	CHEBI_23888
1	CHEBI-CHEBI	CHEBI_22587	CHEBI_48706
1	CHEBI-CHEBI	CHEBI_23888	CHEBI_48706

2|chunk|Viruses 2018, 10, 669 2 of 12 with several notable cell surface and tight junction receptors/co-receptors including heparin sulfate proteoglycans (HSPG), cluster of differentiation 81 (CD81), low density lipoprotein receptor (LDLR), scavenger receptor class B type I (SR-BI), claudin-1 (CLDN1), and occludin (OCLN) [2, 3] . Additional factors that can influence viral entry include apolipoprotein E (ApoE), which is incorporated on infectious HCV virions [4] , and can function as an exchangeable apolipoprotein between secreted ApoE-associated lipoproteins and the HCV lipoviroparticle (LVP) to enhanced HCV infection [5] .
2	116	123 heparin	Chemical	CHEBI_28304
2	116	131 heparin sulfate	Chemical	CHEBI_28815
2	124	131 sulfate	Chemical	CHEBI_16189
2	132	145 proteoglycans	Chemical	CHEBI_37396
2	154	161 cluster	Chemical	CHEBI_33731
2	204	215 lipoprotein	Chemical	CHEBI_6495
2	382	396 apolipoprotein	Chemical	CHEBI_39015
2	497	511 apolipoprotein	Chemical	CHEBI_39015
2	545	557 lipoproteins	Chemical	CHEBI_6495
2	588	591 LVP	Chemical	CHEBI_6603
2	CHEBI-CHEBI	CHEBI_28304	CHEBI_28815
2	CHEBI-CHEBI	CHEBI_28304	CHEBI_16189
2	CHEBI-CHEBI	CHEBI_28304	CHEBI_37396
2	CHEBI-CHEBI	CHEBI_28304	CHEBI_33731
2	CHEBI-CHEBI	CHEBI_28304	CHEBI_6495
2	CHEBI-CHEBI	CHEBI_28304	CHEBI_39015
2	CHEBI-CHEBI	CHEBI_28304	CHEBI_6603
2	CHEBI-CHEBI	CHEBI_28815	CHEBI_16189
2	CHEBI-CHEBI	CHEBI_28815	CHEBI_37396
2	CHEBI-CHEBI	CHEBI_28815	CHEBI_33731
2	CHEBI-CHEBI	CHEBI_28815	CHEBI_6495
2	CHEBI-CHEBI	CHEBI_28815	CHEBI_39015
2	CHEBI-CHEBI	CHEBI_28815	CHEBI_6603
2	CHEBI-CHEBI	CHEBI_16189	CHEBI_37396
2	CHEBI-CHEBI	CHEBI_16189	CHEBI_33731
2	CHEBI-CHEBI	CHEBI_16189	CHEBI_6495
2	CHEBI-CHEBI	CHEBI_16189	CHEBI_39015
2	CHEBI-CHEBI	CHEBI_16189	CHEBI_6603
2	CHEBI-CHEBI	CHEBI_37396	CHEBI_33731
2	CHEBI-CHEBI	CHEBI_37396	CHEBI_6495
2	CHEBI-CHEBI	CHEBI_37396	CHEBI_39015
2	CHEBI-CHEBI	CHEBI_37396	CHEBI_6603
2	CHEBI-CHEBI	CHEBI_33731	CHEBI_6495
2	CHEBI-CHEBI	CHEBI_33731	CHEBI_39015
2	CHEBI-CHEBI	CHEBI_33731	CHEBI_6603
2	CHEBI-CHEBI	CHEBI_6495	CHEBI_39015
2	CHEBI-CHEBI	CHEBI_6495	CHEBI_6603
2	CHEBI-CHEBI	CHEBI_39015	CHEBI_6603

3|chunk|There are over 170 million HCV carriers worldwide. HCV infection can lead to chronic hepatitis, cirrhosis, and liver cancer, and there is still no effective vaccine against the virus. While the previous standard of care consisting of PEGylated-interferon (IFN)- in combination with ribavirin is associated with several important drawbacks including severe side effects and low efficacy against HCV genotype 1, the recent introduction of the direct-acting antivirals (DAAs) targeting the viral non-structural proteins has substantially improved the sustained virological response (SVR) in the most difficult to treat genotype 1 patients [6] . However, the DAAs also have challenges including potential toxicity, especially from drug-drug interactions (DDIs). For instance, HCV protease inhibitors are at high risk for DDIs as they are known substrates and inhibitors of cytochrome P450 (CYP) 3A4 system and can interfere with the metabolism of other drugs including immunosuppressants (e.g. cyclosporine and tacrolimus) when co-administered in liver transplant setting [7] . Other drug-drug interactions from HCV DAAs include those with acid-suppression therapies (e.g. famotidine and omeprazole) or the human immunodeficiency virus (HIV) antiretroviral agents (e.g. Rilpivirine and Efavirenz), which have been shown to decrease the effectiveness of the HCV NS5A inhibitor Ledipasvir [8] and produce adverse drug reactions with the protease inhibitor Paritaprevir [7], respectively. In addition, due to the great genetic variability of HCV, selection of resistant mutants is becoming a challenge as a greater number of people are being treated in real-world settings, which can potentially lead to DAA failures [6, 9] . Therefore, continuous identification of novel candidate drugs particularly with a different mode of action to improve the current therapeutic strategies is highly envisaged.
3	31	39 carriers	Chemical	CHEBI_78059
3	283	292 ribavirin	Chemical	CHEBI_63580
3	456	466 antivirals	Chemical	CHEBI_22587
3	509	517 proteins	Chemical	CHEBI_36080
3	777	796 protease inhibitors	Chemical	CHEBI_37670
3	786	796 inhibitors	Chemical	CHEBI_35222
3	856	866 inhibitors	Chemical	CHEBI_35222
3	870	880 cytochrome	Chemical	CHEBI_4056
3	870	885 cytochrome P450	Chemical	CHEBI_38559
3	887	890 CYP	Chemical	CHEBI_38559
3	950	955 drugs	Chemical	CHEBI_23888
3	991	1003 cyclosporine	Chemical	CHEBI_4031
3	1008	1018 tacrolimus	Chemical	CHEBI_61049
3	1170	1180 famotidine	Chemical	CHEBI_4975
3	1185	1195 omeprazole	Chemical	CHEBI_7772
3	1267	1278 Rilpivirine	Chemical	CHEBI_68606
3	1358	1372 NS5A inhibitor	Chemical	CHEBI_83799
3	1363	1372 inhibitor	Chemical	CHEBI_35222
3	1373	1383 Ledipasvir	Chemical	CHEBI_85089
3	1408	1412 drug	Chemical	CHEBI_23888
3	1432	1450 protease inhibitor	Chemical	CHEBI_37670
3	1441	1450 inhibitor	Chemical	CHEBI_35222
3	1451	1463 Paritaprevir	Chemical	CHEBI_85188
3	1776	1781 drugs	Chemical	CHEBI_23888
3	1820	1826 action	Chemical	CHEBI_5133
3	CHEBI-CHEBI	CHEBI_78059	CHEBI_63580
3	CHEBI-CHEBI	CHEBI_78059	CHEBI_22587
3	CHEBI-CHEBI	CHEBI_78059	CHEBI_36080
3	CHEBI-CHEBI	CHEBI_78059	CHEBI_37670
3	CHEBI-CHEBI	CHEBI_78059	CHEBI_35222
3	CHEBI-CHEBI	CHEBI_78059	CHEBI_4056
3	CHEBI-CHEBI	CHEBI_78059	CHEBI_38559
3	CHEBI-CHEBI	CHEBI_78059	CHEBI_23888
3	CHEBI-CHEBI	CHEBI_78059	CHEBI_4031
3	CHEBI-CHEBI	CHEBI_78059	CHEBI_61049
3	CHEBI-CHEBI	CHEBI_78059	CHEBI_4975
3	CHEBI-CHEBI	CHEBI_78059	CHEBI_7772
3	CHEBI-CHEBI	CHEBI_78059	CHEBI_68606
3	CHEBI-CHEBI	CHEBI_78059	CHEBI_83799
3	CHEBI-CHEBI	CHEBI_78059	CHEBI_85089
3	CHEBI-CHEBI	CHEBI_78059	CHEBI_85188
3	CHEBI-CHEBI	CHEBI_78059	CHEBI_5133
3	CHEBI-CHEBI	CHEBI_63580	CHEBI_22587
3	CHEBI-CHEBI	CHEBI_63580	CHEBI_36080
3	CHEBI-CHEBI	CHEBI_63580	CHEBI_37670
3	CHEBI-CHEBI	CHEBI_63580	CHEBI_35222
3	CHEBI-CHEBI	CHEBI_63580	CHEBI_4056
3	CHEBI-CHEBI	CHEBI_63580	CHEBI_38559
3	CHEBI-CHEBI	CHEBI_63580	CHEBI_23888
3	CHEBI-CHEBI	CHEBI_63580	CHEBI_4031
3	CHEBI-CHEBI	CHEBI_63580	CHEBI_61049
3	CHEBI-CHEBI	CHEBI_63580	CHEBI_4975
3	CHEBI-CHEBI	CHEBI_63580	CHEBI_7772
3	CHEBI-CHEBI	CHEBI_63580	CHEBI_68606
3	CHEBI-CHEBI	CHEBI_63580	CHEBI_83799
3	CHEBI-CHEBI	CHEBI_63580	CHEBI_85089
3	CHEBI-CHEBI	CHEBI_63580	CHEBI_85188
3	CHEBI-CHEBI	CHEBI_63580	CHEBI_5133
3	CHEBI-CHEBI	CHEBI_22587	CHEBI_36080
3	CHEBI-CHEBI	CHEBI_22587	CHEBI_37670
3	CHEBI-CHEBI	CHEBI_22587	CHEBI_35222
3	CHEBI-CHEBI	CHEBI_22587	CHEBI_4056
3	CHEBI-CHEBI	CHEBI_22587	CHEBI_38559
3	CHEBI-CHEBI	CHEBI_22587	CHEBI_23888
3	CHEBI-CHEBI	CHEBI_22587	CHEBI_4031
3	CHEBI-CHEBI	CHEBI_22587	CHEBI_61049
3	CHEBI-CHEBI	CHEBI_22587	CHEBI_4975
3	CHEBI-CHEBI	CHEBI_22587	CHEBI_7772
3	CHEBI-CHEBI	CHEBI_22587	CHEBI_68606
3	CHEBI-CHEBI	CHEBI_22587	CHEBI_83799
3	CHEBI-CHEBI	CHEBI_22587	CHEBI_85089
3	CHEBI-CHEBI	CHEBI_22587	CHEBI_85188
3	CHEBI-CHEBI	CHEBI_22587	CHEBI_5133
3	CHEBI-CHEBI	CHEBI_36080	CHEBI_37670
3	CHEBI-CHEBI	CHEBI_36080	CHEBI_35222
3	CHEBI-CHEBI	CHEBI_36080	CHEBI_4056
3	CHEBI-CHEBI	CHEBI_36080	CHEBI_38559
3	CHEBI-CHEBI	CHEBI_36080	CHEBI_23888
3	CHEBI-CHEBI	CHEBI_36080	CHEBI_4031
3	CHEBI-CHEBI	CHEBI_36080	CHEBI_61049
3	CHEBI-CHEBI	CHEBI_36080	CHEBI_4975
3	CHEBI-CHEBI	CHEBI_36080	CHEBI_7772
3	CHEBI-CHEBI	CHEBI_36080	CHEBI_68606
3	CHEBI-CHEBI	CHEBI_36080	CHEBI_83799
3	CHEBI-CHEBI	CHEBI_36080	CHEBI_85089
3	CHEBI-CHEBI	CHEBI_36080	CHEBI_85188
3	CHEBI-CHEBI	CHEBI_36080	CHEBI_5133
3	CHEBI-CHEBI	CHEBI_37670	CHEBI_35222
3	CHEBI-CHEBI	CHEBI_37670	CHEBI_4056
3	CHEBI-CHEBI	CHEBI_37670	CHEBI_38559
3	CHEBI-CHEBI	CHEBI_37670	CHEBI_23888
3	CHEBI-CHEBI	CHEBI_37670	CHEBI_4031
3	CHEBI-CHEBI	CHEBI_37670	CHEBI_61049
3	CHEBI-CHEBI	CHEBI_37670	CHEBI_4975
3	CHEBI-CHEBI	CHEBI_37670	CHEBI_7772
3	CHEBI-CHEBI	CHEBI_37670	CHEBI_68606
3	CHEBI-CHEBI	CHEBI_37670	CHEBI_83799
3	CHEBI-CHEBI	CHEBI_37670	CHEBI_85089
3	CHEBI-CHEBI	CHEBI_37670	CHEBI_85188
3	CHEBI-CHEBI	CHEBI_37670	CHEBI_5133
3	CHEBI-CHEBI	CHEBI_35222	CHEBI_4056
3	CHEBI-CHEBI	CHEBI_35222	CHEBI_38559
3	CHEBI-CHEBI	CHEBI_35222	CHEBI_23888
3	CHEBI-CHEBI	CHEBI_35222	CHEBI_4031
3	CHEBI-CHEBI	CHEBI_35222	CHEBI_61049
3	CHEBI-CHEBI	CHEBI_35222	CHEBI_4975
3	CHEBI-CHEBI	CHEBI_35222	CHEBI_7772
3	CHEBI-CHEBI	CHEBI_35222	CHEBI_68606
3	CHEBI-CHEBI	CHEBI_35222	CHEBI_83799
3	CHEBI-CHEBI	CHEBI_35222	CHEBI_85089
3	CHEBI-CHEBI	CHEBI_35222	CHEBI_85188
3	CHEBI-CHEBI	CHEBI_35222	CHEBI_5133
3	CHEBI-CHEBI	CHEBI_4056	CHEBI_38559
3	CHEBI-CHEBI	CHEBI_4056	CHEBI_23888
3	CHEBI-CHEBI	CHEBI_4056	CHEBI_4031
3	CHEBI-CHEBI	CHEBI_4056	CHEBI_61049
3	CHEBI-CHEBI	CHEBI_4056	CHEBI_4975
3	CHEBI-CHEBI	CHEBI_4056	CHEBI_7772
3	CHEBI-CHEBI	CHEBI_4056	CHEBI_68606
3	CHEBI-CHEBI	CHEBI_4056	CHEBI_83799
3	CHEBI-CHEBI	CHEBI_4056	CHEBI_85089
3	CHEBI-CHEBI	CHEBI_4056	CHEBI_85188
3	CHEBI-CHEBI	CHEBI_4056	CHEBI_5133
3	CHEBI-CHEBI	CHEBI_38559	CHEBI_23888
3	CHEBI-CHEBI	CHEBI_38559	CHEBI_4031
3	CHEBI-CHEBI	CHEBI_38559	CHEBI_61049
3	CHEBI-CHEBI	CHEBI_38559	CHEBI_4975
3	CHEBI-CHEBI	CHEBI_38559	CHEBI_7772
3	CHEBI-CHEBI	CHEBI_38559	CHEBI_68606
3	CHEBI-CHEBI	CHEBI_38559	CHEBI_83799
3	CHEBI-CHEBI	CHEBI_38559	CHEBI_85089
3	CHEBI-CHEBI	CHEBI_38559	CHEBI_85188
3	CHEBI-CHEBI	CHEBI_38559	CHEBI_5133
3	CHEBI-CHEBI	CHEBI_23888	CHEBI_4031
3	CHEBI-CHEBI	CHEBI_23888	CHEBI_61049
3	CHEBI-CHEBI	CHEBI_23888	CHEBI_4975
3	CHEBI-CHEBI	CHEBI_23888	CHEBI_7772
3	CHEBI-CHEBI	CHEBI_23888	CHEBI_68606
3	CHEBI-CHEBI	CHEBI_23888	CHEBI_83799
3	CHEBI-CHEBI	CHEBI_23888	CHEBI_85089
3	CHEBI-CHEBI	CHEBI_23888	CHEBI_85188
3	CHEBI-CHEBI	CHEBI_23888	CHEBI_5133
3	CHEBI-CHEBI	CHEBI_4031	CHEBI_61049
3	CHEBI-CHEBI	CHEBI_4031	CHEBI_4975
3	CHEBI-CHEBI	CHEBI_4031	CHEBI_7772
3	CHEBI-CHEBI	CHEBI_4031	CHEBI_68606
3	CHEBI-CHEBI	CHEBI_4031	CHEBI_83799
3	CHEBI-CHEBI	CHEBI_4031	CHEBI_85089
3	CHEBI-CHEBI	CHEBI_4031	CHEBI_85188
3	CHEBI-CHEBI	CHEBI_4031	CHEBI_5133
3	CHEBI-CHEBI	CHEBI_61049	CHEBI_4975
3	CHEBI-CHEBI	CHEBI_61049	CHEBI_7772
3	CHEBI-CHEBI	CHEBI_61049	CHEBI_68606
3	CHEBI-CHEBI	CHEBI_61049	CHEBI_83799
3	CHEBI-CHEBI	CHEBI_61049	CHEBI_85089
3	CHEBI-CHEBI	CHEBI_61049	CHEBI_85188
3	CHEBI-CHEBI	CHEBI_61049	CHEBI_5133
3	CHEBI-CHEBI	CHEBI_4975	CHEBI_7772
3	CHEBI-CHEBI	CHEBI_4975	CHEBI_68606
3	CHEBI-CHEBI	CHEBI_4975	CHEBI_83799
3	CHEBI-CHEBI	CHEBI_4975	CHEBI_85089
3	CHEBI-CHEBI	CHEBI_4975	CHEBI_85188
3	CHEBI-CHEBI	CHEBI_4975	CHEBI_5133
3	CHEBI-CHEBI	CHEBI_7772	CHEBI_68606
3	CHEBI-CHEBI	CHEBI_7772	CHEBI_83799
3	CHEBI-CHEBI	CHEBI_7772	CHEBI_85089
3	CHEBI-CHEBI	CHEBI_7772	CHEBI_85188
3	CHEBI-CHEBI	CHEBI_7772	CHEBI_5133
3	CHEBI-CHEBI	CHEBI_68606	CHEBI_83799
3	CHEBI-CHEBI	CHEBI_68606	CHEBI_85089
3	CHEBI-CHEBI	CHEBI_68606	CHEBI_85188
3	CHEBI-CHEBI	CHEBI_68606	CHEBI_5133
3	CHEBI-CHEBI	CHEBI_83799	CHEBI_85089
3	CHEBI-CHEBI	CHEBI_83799	CHEBI_85188
3	CHEBI-CHEBI	CHEBI_83799	CHEBI_5133
3	CHEBI-CHEBI	CHEBI_85089	CHEBI_85188
3	CHEBI-CHEBI	CHEBI_85089	CHEBI_5133
3	CHEBI-CHEBI	CHEBI_85188	CHEBI_5133

4|chunk|Rhizoma Coptidis (RC) is the dried rhizome typically obtained from Coptis chinensis Franch ('Chinese goldthread'), which is a medicinal plant of the Ranunculaceae family [10]. RC is one of the most commonly used Chinese medicinal herbs (also known as 'Huang Lian') documented by the WHO [10] and is known to contain various bioactive alkaloids [11] . It is traditionally used for its "heat clearing" and "detoxification" effects such as treatment against arthritis, burns, eczema, microbial infections, and gastrointestinal diseases [10, 12, 13 ]. In addition, RC's traditional usage against infections has been correlated through several recent studies that validated its antimicrobial functions, including against several bacteria and viruses [13] . Specifically, RC and its major constituents have been shown to exert inhibitory effects against herpesvirus, respiratory syncytial virus, and mouse hepatitis A virus infections [14] [15] [16] . These precedents suggest that RC may be a potent source for the discovery of novel antiviral treatments. Since the effect of RC on HCV infection remains largely unexplored, and in an attempt to identify novel anti-HCV agents, in this study we examined the impact of the methanolic extract of RC on HCV infection. Our results demonstrated that RC could robustly inhibit HCV infection by targeting the early steps in viral entry. Specifically, the targeted steps included viral attachment and entry/fusion into the host cells. In addition, the RC-mediated inhibition of HCV is not genotype-specific as the drug equally inhibits other HCV genotypes, thereby identifying RC as a potential pan-genotypic anti-HCV agent.
4	334	343 alkaloids	Chemical	CHEBI_22315
4	673	686 antimicrobial	Chemical	CHEBI_33281
4	1029	1038 antiviral	Chemical	CHEBI_22587
4	1550	1554 drug	Chemical	CHEBI_23888
4	CHEBI-CHEBI	CHEBI_22315	CHEBI_33281
4	CHEBI-CHEBI	CHEBI_22315	CHEBI_22587
4	CHEBI-CHEBI	CHEBI_22315	CHEBI_23888
4	CHEBI-CHEBI	CHEBI_33281	CHEBI_22587
4	CHEBI-CHEBI	CHEBI_33281	CHEBI_23888
4	CHEBI-CHEBI	CHEBI_22587	CHEBI_23888

5|chunk|Materials and Methods

6|chunk|Culture of Huh-7.5 cells (human hepatoma, Huh-7 cell derivative) and production of cell-culture derived HCV particles (HCVcc) from the Gaussia luciferase reporter-tagged Jc1FLAG2(p7-nsGluc2A) construct (genotype 2a; kindly provided by Dr. Charles M. Rice) were carried out as previously described [17] . Virus concentration was expressed as multiplicity of infection (MOI) and the

